Skip Navigation
Leading research to understand, treat, and prevent infectious, immunologic, and allergic diseases
Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

FY 2011 NIAID Technology Transfer and Partnerships

NIAID is committed to making sure that NIAID-supported discoveries move steadily from the laboratory toward development into products such as approved vaccines, treatments, or diagnostic tools that improve the public health and advance scientific understanding of underlying causes of disease. Product development is complex and requires innovative approaches to be successful. By fostering collaborative partnerships between NIAID investigators and scientists in industry, academia, non-profits and other government agencies, the NIAID Office of Technology Development (OTD) helps to further the development of products and advance scientific knowledge essential to NIAID’s mission.

OTD accomplishes its mission to facilitate discovery and promote the commercialization of biomedical innovations that can improve the public health using a number of specific mechanisms. These include, but are not limited to, negotiation of technology transfer agreements such as Cooperative Research and Development Agreements (CRADAs), Research Collaboration Agreements (RCAs), and conditional Gift Acceptance letters and through the facilitation and exchange of research materials and information with outside organizations. OTD also manages NIAID’s patent portfolio to provide industry with an incentive to further develop NIAID technology.

Fiscal Year (FY) 2011 NIAID Partnerships and Technology Development Activities

OTD negotiated 8 CRADAs, and 30 Research Collaboration Agreements with industry, academia, non-profits, and other governmental agencies in FY 2011. The research projects under these new agreements focused on a wide variety of topics. The following are just a few examples:

  • Identification of novel therapeutic targets in inflammatory and autoimmune diseases such as asthma and rheumatoid arthritis
  • Development of a passive immunization system against HIV
  • Testing of novel anthrax lethal toxin inhibitors
  • Development of novel vaccine and treatment strategies against malaria and viral infections
  • Investigations into viruses of the Filoviridae family including Marburg and Ebola

OTD collaborated with the National Institutes of Health (NIH) Office of Technology Transfer (OTT) to attract investment partners for further research and development of NIAID technologies in NIAID’s patent portfolio by announcing opportunities for licensing and collaboration. Examples of such opportunities include

  • Technology related to a prospective vaccine candidate against hepatitis E virus
  • Collaborative opportunity to develop, evaluate, or commercialize Bacillus anthracis vaccines, and B. anthracis protein production
  • An improved detection system for early stage lymphatic filariasis

NIAID leverages patents to attract partners to develop and commercialize its inventions. Historically, NIAID inventions, both patented and unpatented, have led to improved health for millions of people in the United States and around the world. In FY 2011, NIAID recognized NIAID inventors under its new Inventor Award Program for their contributions to the U.S. patents listed below.

  • United States patent US 7,947,289, Multimeric protein toxins to target cells having multiple identifying characteristics.
  • United States patent US 7,932,074. Multivalent human-bovine rotavirus vaccine.
  • United States patent US 7,820,181. Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens.
  • United States patent US 7,820,182. Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions.
  • United States patent US 7,910,105. Methods for treating and preventing fibrosis.
  • United States patent US 7,914,788. Monoclonal antibodies against orthopoxviruses.

In FY 2011, OTD participated in the Biotechnology Industry Organization International Convention in Washington, DC. NIAID staff shared information about technologies which arose from the intramural program and that are available for licensing or collaboration, and discussed NIAID programs with scientists and industry representatives attending the conference.

To support the NIAID mission to address developmental therapeutics for rare and neglected tropical diseases (NTDs), OTD worked with OTT to identify and contribute NIAID intellectual property to the World Intellectual Property Organization’s Re:Search. Re:Search is a new consortium of public and private sector organizations, including NIH, that share intellectual property and expertise with the global health research community to promote the development of new drugs, vaccines, and diagnostics to treat NTDs, malaria, and tuberculosis.

NIAID Technology Transfer Activities1

Fiscal Year Total Number of U.S. Patents in Force at End of FY New License Agreements Signed in FY Total Active CRADAs
2006 217 31 48
2007 227 25 47
2008 236 30 46
2009 224 30 45
2010 217 31 45
2011 198 22 40

1Table displays activities resulting from NIAID intramural research. Data show patents and CRADAs in force on September 30 of the fiscal year indicated, as well as licenses signed within the fiscal year indicated.​

Last Updated June 15, 2012